00013 HUTCHMED
- 34.450
- -0.250-0.72%
HUTCHMED News
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer
Hutchmed (HCM) said Tuesday it started a phase 2/3 trial of its drug candidate surufatinib in combination with nab-paclitaxel, gemcitabine and Jiangsu Hengrui's camrelizumab as a first-line treatment
Reported Earlier, HUTCHMED Initiates The RAPHAEL Registrational Phase III Trial Of HMPL-306 For Patients With IDH1- And/Or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia In China
HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of IDH1 and IDH2 have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors, particularly am
Reported Earlier, HUTCHMED Initiates Phase II/III Trial Of The Combination Of Surufatinib And Camrelizumab For Treatment-Naïve Pancreatic Ductal Adenocarcinoma In Collaboration With Hengrui
Almost half a million people diagnosed each year across the globe —Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib
HUTCHMED Tests New Therapy for Pancreatic Cancer
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%
Hutchmed (HKG:0013) started its phase 2/3 trial for the combination of surufatinib and camrelizumab in patients with metastatic pancreatic ductal adenocarcinoma in China, according to a Tuesday filing
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China
Hutchmed (HKG:0013) began its phase 3 trials for the HMPL-306 drug in patients with mutated isocitrate dehydrogenase 1 or 2 relapsed or refractory acute myeloid leukemia in China, according to a Tuesd
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Hehuang Pharmaceutical (00013.HK): Initiating a RAPHAEL registered phase III study on HMPL-306 in the treatment of relapsed/refractory acute myeloid leukemia patients with IDH1 and/or IDH2 mutations in China
On May 14, Ge Longhui Pharmaceutical (00013.HK) announced today the launch of a registered phase clinical trial of HMPL-306 to treat relapsed/refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase (“IDH”) 1 or 2 mutations in China. The first test subject received the first dose of medication on May 11, 2024.
Hehuang Pharmaceutical (00013.HK) and Hengrui Pharmaceutical reached a cooperation and initiated a phase II/III study on surufatinib (surufatinib) combined with camrelizumab (camrelizumab) in the treatment of primary pancreatic ductal adenocarcinoma
Gelonghui, May 14, 丨 Hehuang Pharmaceutical (00013.HK) announced the launch of a Chinese phase II/III clinical trial today to evaluate Hehuang Pharmaceutical's drug candidate surufatinib (surufatinib), the PD-1 antibody camrelizumab (camrelizumab) of Jiangsu Hengrui Pharmaceutical Co., Ltd. (“Hengrui Pharmaceutical”), albumin-conjugated paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of metastatic pancreatic conduction Ductal adenocarcinoma (PDAC) patients
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration With Hengrui
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phase II/III trial to evaluate the efficacy of a combination of the HUTCHMED drug candidate surufatinib, the Jiangsu Hengrui Pharmaceuticals Co., Ltd PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China.
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients With IDH1- And/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase ("IDH") 1 or 2 relapsed / refractory acute myeloid leukemia ("AML") in China. The first patient received their first dose on May 11, 2024.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Hewang Pharmaceutical (0013.HK) Company Follow-up Review: Sales of furoquintinib exceeded expectations and overseas sales continued to accelerate
Incident: Following the approval of fruquintinib in the US in 2023.11, Takeda disclosed the 2023 financial report. As of 2024.03.31, the sales volume of the US quintinib was approximately 6,700 cubic meters, excluding 15.1 million in 202304
Huhuang Pharmaceutical (00013.HK): Fruquintinib sales in the US exceed expectations, are catalytically intensive
Company events. Takeda released its fiscal year 2023 annual report, in which FRUZAQLA (fruquintinib) has been on the market since November 2023, and sales revenue in the US reached 101 as of March 31, 2024
6-K: Report of foreign private issuer (related to financial reporting)
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones gaining around 100 points on Thursday.Shares of Spectrum Brands Holdings, Inc. (NYSE:SPB) rose sharply during Thursday's session following upbeat earnings.Sp
HUTCHMED Welcomes New Board Member Expertise
Hehuang Pharmaceutical (00013): Yan Siya was appointed as an independent non-executive director
Zhitong Finance App News, Hehuang Pharmaceutical (00013) issued an announcement. Dr. Yan Siya was appointed as the company's independent non-executive director and technical committee member, effective May 13, 2024.
Hehuang Pharmaceutical (00013.HK): Yan Siya Appointed as Independent Non-Executive Director
On May 8, Ge Longhui Pharmaceutical (00013.HK) issued an announcement. Yan Siya was appointed as the company's independent non-executive director and technical committee member, effective May 13, 2024.
HUTCHMED Appoints New Board Director
Analysis
Price Target
No Data
